RENNIE DUO
Country: Ireland
Language: English
Source: HPRA (Health Products Regulatory Authority)
Summary of Product characteristics
(SPC)
26-05-2024
Some documents for this product are not currently available, you can send a request to our customer service and we will notify you as soon as we are able to obtain them.
Send request.
Send request.
Active ingredient:
ALGINIC ACID CALCIUM CARBONATE MAGNESIUM CARBONATE
Available from:
Bayer PLC
Dosage:
300/1250/147 %v/v
Pharmaceutical form:
Tablets Chewable
Authorization date:
2006-04-28
Summary of Product characteristics
PART II
SUMMARY OF PRODUCT CHARACTERISTICS
1 NAME OF THE MEDICINAL PRODUCT
Rennie Duo Chewable Tablet
2 QUALITATIVE AND QUANTITATIVE COMPOSITION
Each tablet of 3,486 mg contains the following active substances:
alginic acid 300 mg, calcium carbonate 1,250 mg and heavy magnesium carbonate 147 mg.
For excipients, see section 6.1.
3 PHARMACEUTICAL FORM
Chewable tablet
White tablet with bevelled edges.
4 CLINICAL PARTICULARS
4.1 THERAPEUTIC INDICATIONS
Symptomatic treatment of complaints resulting from gastro-oesophageal reflux and hyperacidity, such as regurgitation
and heartburn.
4.2 POSOLOGY AND METHOD OF ADMINISTRATION
The usual dose is 1 tablet to be chewed. It should preferably be taken one hour after meals and before going to bed. An
additional dose of 1 tablet can also be taken in between in the case of heartburn. Do not take more than 8 tablets in any
24-hour period. Only for use by adults (over 12 years of age).
4.3 CONTRAINDICATIONS
Severe renal insufficiency, hypercalcaemia and pre-existing hypophosphataemia.
Nephrolithiasis due to calculi containing calcium deposits.
Hypersensitivity to the active substances or to any of the excipients.
4.4 SPECIAL WARNINGS AND PRECAUTIONS FOR USE
Prolonged use should be avoided.
If the symptoms persist or only partly disappear, further medical advice should be sought.
As with other antacids, Rennie Duo chewable tablet may mask a malignancy in the stomach.
In general, caution should be exercised in patients with impaired renal function.
If Rennie Duo chewable tablet is used in such patients, plasma concentrations of calcium and magnesium should be
monitored regularly.
Prolonged use of high doses may result in undesirable side-effects such as hypercalcaemia, magnesaemia and the milk
alkali syndrome, particularly in patients suffering fr
Read the complete document
